Payment overview · 2025
General Payments
$102.05
5 reported records · 4 companies
Healthcare provider profile · identity verified
William Boyd Roberson, DO
Allopathic & Osteopathic Physicians|Family Medicine · HENDERSON, TX · NPI 1750386413
Verified facts
What the public records show
CMS Open Payments records show William Boyd Roberson, DO received $102.05 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 37.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Ozempic.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.27 | 37.5% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $27.29 | 26.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.61 | 21.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.88 | 14.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $102.05 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 177 | 59 |
| Alprazolam | Alprazolam | 156 | 26 |
| Gabapentin | Gabapentin | 148 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 125 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 121 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 37 |
| Montelukast Sodium | Montelukast Sodium | 118 | 51 |
| Lisinopril | Lisinopril | 111 | 45 |
| Tramadol Hcl | Tramadol Hcl | 108 | 24 |
| Potassium Chloride | Potassium Chloride | 101 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 20 |
| Furosemide | Furosemide | 92 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 23 |
| Omeprazole | Omeprazole | 88 | 32 |
| Metformin Hcl | Metformin Hcl | 85 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 26 |
| Losartan Potassium | Losartan Potassium | 71 | 29 |
| Simvastatin | Simvastatin | 71 | 21 |
| Alendronate Sodium | Alendronate Sodium | 62 | 17 |
| Carvedilol | Carvedilol | 56 | 17 |
| Jardiance | Empagliflozin | 53 | 13 |
| Mounjaro | Tirzepatide | 53 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 19 |
| Clonazepam | Clonazepam | 49 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 17 |
| Meloxicam | Meloxicam | 47 | 14 |
| Ozempic | Semaglutide | 47 | 13 |
| Trazodone Hcl | Trazodone Hcl | 42 | 21 |
| Allopurinol | Allopurinol | 41 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | suppressed |
| Nystatin | Nystatin | 41 | 13 |
| Diazepam | Diazepam | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 16 |
| Pregabalin | Pregabalin | 37 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 36 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Dutasteride | Dutasteride | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 12 |
| Prednisone | Prednisone | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 21 |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | 12 |
| Fluconazole | Fluconazole | 23 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 17 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $102.05 · 5 records | Novo Nordisk Inc | CAPVAXIVE, ELIQUIS, GARDASIL 9, INGREZZA, NURTEC ODT, Ozempic, ROTATEQ, Rybelsus, VAXNEUVANCE, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Neurocrine BioSciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error